Ondansetrón Serraclinics (Ondansetron)

Ondansetron is used in the management of nausea and vomiting associated with several therapeutic pathways:

• Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of acute and delayed episodes.
• Radiation‑induced nausea and vomiting (RINV): Helps control nausea during and after radiotherapy.
• Post‑operative nausea and vomiting (PONV): Decreases incidence of nausea and vomiting after surgical procedures.

• Ondansetron selectively blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents serotonin‑mediated activation of the vomiting centre, thereby reducing nausea and vomiting signals.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel movement difficulty.
• Diarrhoea: loose stools, usually transient.
• Fatigue: feeling of tiredness or reduced energy.
• Dizziness: light‑headed sensation.
• Abdominal discomfort: mild stomach pain or cramping.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, potentially leading to torsades de pointes.
• Severe hypersensitivity: rash, itching, swelling, or anaphylaxis.
• Serotonin syndrome: agitation, hyperreflexia, fever, in severe cases.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Neuroleptic malignant‑like syndrome: high fever, muscle rigidity, autonomic instability.

Before prescribing Ondansetrón Serraclinics, consider the following safety points:

• Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed.
• Electrolyte assessment: correct hypokalaemia, hypomagnesemia, or hypocalcaemia before use.
• Concomitant serotonergic drugs: avoid combined use that may increase serotonin syndrome risk.
• Pregnancy: use only if the potential benefit outweighs the risk; discuss with obstetrician.
• Breastfeeding: weigh infant benefits against potential drug exposure through milk.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines that affect cardiac rhythm or serotonin pathways.

Major Interactions (Avoid)

• Anti‑arrhythmic agents (e.g., amiodarone, quinidine): may exacerbate QT prolongation.
• Certain macrolide antibiotics (e.g., erythromycin, clarithromycin): increase risk of cardiac arrhythmias.
• Antifungal azoles (e.g., fluconazole, itraconazole): potentiate QT interval effects.

Moderate Interactions (Monitor Closely)

• Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may raise serotonin syndrome risk.
• Other anti‑emetics (e.g., aprepine‑